Find a participating ALZ-NET site near you

Partnering Organizations

The Alzheimer’s Association, the American College of Radiology (ACR), the American Society of Neuroradiology (ASNR), the Department of Biostatistics, Brown University School of Public Health and the Critical Path Institute, along with other clinical research and imaging experts, has launched the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET).

Our Story

Over six million Americans are living with Alzheimer’s disease (AD) or a related dementia. The field is entering a new phase of treatment and care with more than 140 AD therapies being tested in clinical trials and some currently under regulatory review. The Alzheimer’s Association convened a group of clinical research and imaging experts in 2021 to develop a network that evaluates the longitudinal outcomes of patients treated with novel FDA-approved AD therapies in real-world settings. In August 2022, the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) was launched.

ALZ-NET is a provider-enrolled network that collects real-world clinical and imaging data from patients being evaluated for or being treated with novel FDA-approved AD therapies.  Novel FDA-approved therapies for AD are drugs that have received approval as treatments for Alzheimer's disease (AD) from the U.S. Food and Drug Administration since 2021.  ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative, inclusive research and supporting opportunities to improve care.  

The Alzheimer's Network for Treatment and Diagnostics is approved by the Centers for Medicare and Medicaid Services (CMS) as a Coverage with Evidence Development (CED) study and can be used as a pathway to Medicare coverage for anti-amyloid Alzheimer's therapies that have received traditional (full) FDA approval. This currently includes Leqembi (lecanemab), an anti-amyloid Alzheimer's disease treatment that has traditional FDA approval.


Meet the Leadership Team

Co-Principal Investigators

ALZ-NET is led by a team of co-principal investigators (Co-PIs) that have extensive experience in clinical research of Alzheimer’s disease and related dementia (ADRD). The Co-PIs have assembled a multidisciplinary group of industry respected and published individuals to form an advisory committee. This advisory committee serves to provide expertise and guidance in their respected domain as it pertains to dementia care and/or clinical research. Under the direction of the Co-PIs, ALZ-NET is ideally suited for the ongoing development, conduct, and output of ALZ-NET.

leader profile image
Maria C. Carrillo, PhD
Alzheimer’s Association
Chicago, IL
leader profile image
Gil D. Rabinovici, MD
Memory and Aging Center, University of California, San Francisco
San Francisco, CA
leader profile image
Michael S. Rafii, MD, PhD
Keck School of Medicine, University of Southern California
San Diego, CA


Ali Atri, MD
Banner Sun Health Research Institute
Sun City, AZ
Kirk Daffner, MD
Harvard Medical School
Boston, MA
Rebecca M. Edelmayer, PhD
Alzheimer's Association
Chicago, IL
Constantine Gatsonis, PhD
Brown University School of Public Health
Providence, RI
Oscar Lopez, MD, FAAN
University of Pittsburgh School of Medicine
Pittsburgh, PA
Andrew W. March, MHA
American College of Radiology
Philadelphia, PA
Anton P. Porsteinsson, MD
University of Rochester School of Medicine
Rochester, NY
Katherine Possin, PhD
Memory and Aging Center. University of California, San Francisco
San Franscisco, CA
Stephen Salloway, MD
Butler Hospital/Warren Alpert Medical School of Brown University
Providence, RI
Mary Sano, PhD
Mount Sinai School of Medicine
New York, NY
Heather Snyder, PhD
Alzheimer’s Association
Chicago, IL
Christopher Whitlow, MD, PhD, MHA
Wake Forest School of Medicine/American College of Radiology
Winston-Salem, NC
Consuelo Wilkins, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN
Charles Windon, MD
Memory and Aging Center, University of California, San Francisco
San Francisco, CA


Jerome Barakos, MD
Sutter Health California
San Francisco, CA
Sharon Brangman, MD
SUNY Upstate Medical University
Syracuse, NY
Gregory Jicha, MD, PhD
University of Kentucky
Lexington, KY
John Jordan, MD, FACR
American College of Radiology / American Society of Neuroradiology / Providence Little Company of Mary Medical Center – Torrance
Torrance, CA
Jennifer Lingler, PhD, MA, CRNP, FAAN
University of Pittsburgh School of Nursing
Pittsburgh, PA
Klaus Romero, MD, MS
Critical Path Institute
Tucson, AZ
Sudhir Sivahkumaran, PhD
Critical Path Institute
Tucson, AZ

Imaging Work Group

Tammie Benzinger, MD, PhD
Washington University
St. Louis MO
Marc Daniel Benayoun, MD, PhD
Wake Forest School of Medicine
Winston-Salem, NC
Anna Franceschi, MD, PhD
Northwell Healt
New York, NY
Etta Pisano, MD, FACR
American College of Radiology
Reston, VA
Greg Zaharchuk, MD, PhD
Stanford University
Stanford, CA

Steering Committee Oversight


Workgroups and Subcommittees

A steering committee supports the scientific vision of ALZ-NET by monitoring progress against established timelines, evaluating scientific program initiatives, ensuring publication and dissemination of data, and approving budgets while monitoring financial compliance.   The steering committee creates workgroups and subcommittees as needed to perform additional functional roles. Established subcommittees include, but are not limited to, a Data Access and Publications Committee, a Communications and Recruitment Committee, an Imaging Committee, and a Data Management Committee.


Find medical professionals in your area who are participating in ALZ-NET.

Find a Site